Form D · Pharmaceuticals
TREVENA INC
King Of Prussia, PA · CIK 0001429560
Offering snapshot reported May 17, 2013 · SEC filing
- Reported sold
- $60M Offering amount: $60M
- Investors reported
- 9 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 3, 2013 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 17, 2013 | Initial | $59,999,997 | No comparison | 9 | SEC filing |
| Jul 16, 2010 | Initial | $17,500,000 | No comparison | 8 | SEC filing |
| Mar 10, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity, Other
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-196667
Includes shares of Common Stock issuable upon conversion of Preferred Stock
Source: Form D, filed May 17, 2013. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Farah Champsi | Director |
| Robert Garland | Director |
| Maxine Gowen | Director, Executive |
| Terence Mc Guire | Director |
| Christopher Mirabelli | Director |
| Lonnie Moulder, Jr. | Director |
| Robert, Jr. Ruffolo | Director |
| Ralph Snyderman | Director |
| David Solomon | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
1018 West 8 Th Avenue, Suite A
King Of Prussia, PA, 19406
King Of Prussia, PA, 19406